SHR6508 vs Upacicalcet

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Chronic Kidney Disease

Shared mechanism: Calcium-sensing receptor (CaSR) · full Chronic Kidney Disease pipeline

SHR6508

Developed by Jiangsu Hengrui Pharmaceuticals and partners

Phase 3 in Chronic Kidney Diseasesmall molecule
Weak signal

NCT06236295 · Phase 2 · completed

The study is a single-group, unblinded trial of 303 participants, with no placebo or active comparator. Its primary endpoint is the incidence and severity of adverse events, but results are not posted, so whether this endpoint was met cannot be determined.

No aligned efficacy figure on record for this race.

Upacicalcet · UPASITA

Marketed by Sanwa Kagaku Kenkyusho under a licence from EA Pharma

Phase 3 in Chronic Kidney Diseasesmall molecule
Partial signal

NCT05836220 · Phase 3 · completed

The study randomly assigned 412 participants to triple-blinded PLS240 or placebo, providing a well-controlled comparison. However, results for the primary iPTH reduction endpoint have not been posted, and this endpoint is a biochemical surrogate rather than a hard clinical or endoscopic outcome.

Caveat: this result is taken from a peer-reviewed publication abstract; the trial registry has not posted results.

Next expected readout: February 2032 · NCT07890584 (registry estimate)

Reported efficacy

The proportion of PLS240 treated participants compared to the portion of placebo treated participants with a ≥30% decrease in mean iPTH (each visit from screening through week 27); Open-Label Phase: Proportion of participants with a corrected serum calcium (cCa) <7.5 mg/dL (up to week 28); Open-Label Phase: Proportion of participants with a corrected serum calcium (cCa) <8.3 mg/dL (up to week 28); Open-Label Phase: Number of AE's (up to week 28); Open-Label Phase: Number of SAE's (up to week 28): PATH-2, primary endpoint (iPTH reduction of at least 30%), upacicalcet vs placebo: 43.5% versus 17.4%, for a difference in proportions of 26.1% (95% confidence interval, 17.4 to 34.8, P < 0.001) (J Am Soc Nephrol, 2026-10-23). (met)

Result source: NCT05836220

Results for Chronic Kidney Disease

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointSHR6508Upacicalcet
Kidney composite outcome—Not reported—Not posted · NCT05832931
UACR, % change—Not reported—Not posted · NCT05832931
eGFR slope—Not reported—Not posted · NCT05832931
Haemoglobin, change—Not reported—Not posted · NCT05832931

Kidney composite outcome

SHR6508
—Not reported
Upacicalcet
—Not posted · NCT05832931

UACR, % change

SHR6508
—Not reported
Upacicalcet
—Not posted · NCT05832931

eGFR slope

SHR6508
—Not reported
Upacicalcet
—Not posted · NCT05832931

Haemoglobin, change

SHR6508
—Not reported
Upacicalcet
—Not posted · NCT05832931
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

SHR6508: no structured comparison results are available for Chronic Kidney Disease.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

Upacicalcet
PATH-2, primary endpoint (iPTH reduction of at least 30%), upacicalcet vs placebo: 43.5% versus 17.4%, for a difference in proportions of 26.1% (95% confidence interval, 17.4 to 34.8, P < 0.001) (J Am Soc Nephrol, 2026-10-23). NCT05836220 · Phase 3 · design grade: moderate · publication or press release
PATH-1, primary endpoint (iPTH reduction of at least 30%), upacicalcet vs placebo: 42.1% versus 16.8%, for a difference in proportions of 25.3% (95% confidence interval, 16.2 to 34.5, P < 0.001) (J Am Soc Nephrol, 2026-10-23). NCT05832931 · Phase 3 · design grade: moderate · publication or press release

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: SHR6508's landscape · Upacicalcet's landscape